Press Releases

Press Releases

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

Sep 21, 2023
Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) At closing combined Company will have approximately $13.7 million cash on hand to fund operations into 2H 2024 Upcoming milestones include

Applied Molecular Transport Reports Second Quarter 2023 Financial Results

Aug 14, 2023
Currently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company Cash and Cash Equivalents of $22.5 million, as of June 30, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc.

Applied Molecular Transport Reports First Quarter 2023 Financial Results

May 11, 2023
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2023. Recent Business Highlights Engaged MTS Health Partners, L.P.

Applied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic Alternatives

Mar 27, 2023
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company’s board of directors approved a workforce reduction of approximately 57% of its employee base and the

Applied Molecular Transport Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 09, 2023
Exploring strategic partnership options to advance AMT-101 for chronic pouchitis, an orphan indication with no  FDA-approved products Evaluating next steps for the company's second clinical asset, AMT-126 SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport

Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO ’23 Congress

Mar 03, 2023
New positive data demonstrate oral AMT-101’s gut-restricted profile with tissue-level pharmacodynamics (PD) effects and no systemic exposure by design Translational analysis reveals IL-10 biological responses in both 3mg and 10mg dose arms SOUTH SAN FRANCISCO, Calif., March 03, 2023 (GLOBE